Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01371981
Title Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

acute myeloid leukemia

Therapies

Cytarabine + Daunorubicin + Etoposide

Sorafenib

Cytarabine + Etoposide

Cytarabine + Mitoxantrone

Asparaginase + Cytarabine

Bortezomib

Age Groups: adult | child
Covered Countries USA | CAN


No variant requirements are available.